Regorafenib
|
|
|
- CAS-Nr.
- 755037-03-7
- Englisch Name:
- Regorafenib
- Synonyma:
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;Regorafenib (BAY 73-4506);CS-169;RG-API;CS-1930;Rigofeni;Regafenib;regorafinib;BAY 73-4506;Regorafenib
- CBNumber:
- CB32498792
- Summenformel:
- C21H15ClF4N4O3
- Molgewicht:
- 482.82
- MOL-Datei:
- 755037-03-7.mol
|
Regorafenib Eigenschaften
- Schmelzpunkt:
- 206.0 to 210.0 °C
- Siedepunkt:
- 513.4±50.0 °C(Predicted)
- Dichte
- 1.491±0.06 g/cm3(Predicted)
- storage temp.
- Refrigerator
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 12.04±0.70(Predicted)
- Aggregatzustand
- White powder.
- Farbe
- Pale Pink to Light Pink
- InChI
- InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
- InChIKey
- FNHKPVJBJVTLMP-UHFFFAOYSA-N
- SMILES
- C1(C(NC)=O)=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C(F)=C2)=C1
- CAS Datenbank
- 755037-03-7
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
|
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Regorafenib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In September 2012, theUSFDAapproved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC), especially those for whom standard therapies have failed, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, ananti-EGFRtherapy. Regorafenib is a multikinase inhibitor with potent inhibitory activity versus VEGFRs and PDFRs. Both of these classes of receptors are expressed on tumor cells and affect proliferation and angiogenesis. Regorafenib inhibited growth in murine xenograft models for colon, breast, renal, lung, melanoma, pancreatic, and ovarian tumors when dosed at 10–30 mg/kg. Regorafenib is a fluorinated analog of sorafenib, a multikinase inhibitor co-marketed by Bayer and Onyx for the treatment of kidney and liver cancer. The synthesis of regorafenib is accomplished in two steps from commercially available starting materials. 4-Aminophenol is coupled to 4-chloro-N-methyl- 2-pyridinecarboxamide to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. Subsequent treatment with 4-chloro-3-(trifluoromethyl)phenyl isocycanate affords the urea, regorafenib.
Charakteristisch
Class: receptor tyrosine kinase
Treatment: colorectal cancer, GIST, HCC
Elimination half-life = 26-28 h
Protein binding = 99.5%
Verwenden
BAY 73-4506 (Regorafenib) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf.
Definition
ChEBI: A pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previ
usly received chemotherapy, anti-EGFR or anti-VEGF therapy.
Regorafenib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Regorafenib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 560)Lieferanten
755037-03-7()Verwandte Suche:
- Regorafenib
- BAY 73-4506
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
- BAY 73-4506(Regorafenib)
- 4-(4-(3-(4-chloro-3-(trifluoroMethyl)phenyl)ureido)-3-fluorophenoxy)-N-MethylpicolinaMide
- 4-[4-({[4-chioro-3-(trifluoroMethyl)phenyl]carbaMoyl}aMino)-3-fluorophenoxy]-pyridine-2-carboxylic acid MethylaMide
- REGORAFENIB BAY 73-4506 BAYER HEALTHCARE (SEE ALSO COLORECTAL, LUNG, STOMACH) PHASE II(REGORAFENIB) PHARMACEUTICALS (888) 842-2937WAYNE, NJ
- Regorafenib (BAY 73-4506)
- 4-[4-[[[[4-Chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]-3-fluorophenoxy]-N-Methyl-2-pyridinecarboxaMide
- 4-[4-[N'-(4-Chloro-3-trifluoroMethylphenyl)ureido]-3-
fluorophenoxy]pyridine-2-carboxylic Acid MethylaMide
- regorafinib
- Regafenib
- Reggae sorafenib
- Regorafenib C3X-1410
- Regorafenib, >=98%
- 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea
- Fluoro-Sorafenib
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide Regorafenib BAY 73-4506
- Stivarga(regorafenib)
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide
- 842-2937WAYNE
- China Hot sale Regorafenib with best price and high quality CAS NO.755037-03-7
- CS-1930
- Regorafenib - BAY 73-4506 | Stivarga
- CS-169
- Regorafenib (BAY73-4506,Fluoro-Sorafenib)
- REGORAFENIB; BAY 73-4506; SORAFENIB; BAY-73-4506; BAY 73 4506
- Regorafenib(W.S)
- Re orafenib
- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-3-carboxamide
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-...
- Stannane,tetrakis(5-methylethoxy)-
- α-D-Glucopyranuronicacid,methylester,2,3,5-triacetate
- RG-API
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-met
- Regorafenib,HUVECs,Autophagy,Vascular endothelial growth factor receptor,Colo-205,FGFR,SCFR,RET,NIH-3T3,antiangiogenic,Antitumorigenic,PDGFR,inhibit,c-Kit,HAoSMCs,Platelet-derived growth factor receptor,tumor,Inhibitor,Hep3B cell,CD117,Raf kinases,Fibroblast growth factor receptor,VEGFR,Raf,786-O
- 13C]-Regorafenib
- Rigofeni
- Calcium ion fluorescent probe for colistin h
- Coelenctin-H
- Regorafenib, multikinase inhibitor
- Regorafenib, 10 mM in DMSO
- Regorafenib 98%
- Regorafenib (Standard)
- 755037-03-7
- 755037-07-3
- 755-37-03-7
- 755037-03-8
- C21H15ClF4N4O3
- Inhibitors
- API
- Anti-cancer&immunity
- Amines
- Aromatics
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
